CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH
Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists. Also disclosed are methods for the prophylactic treatment of migraine.
1 . A method of treating breakthrough migraine in a patient undergoing underlying treatment with a migraine medication who has experienced a breakthrough resulting in a migraine headache, symptom or episode, said method comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a breakthrough CGRP antagonist, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the migraine medication used in the underlying treatment is a biologic and wherein the breakthrough CGRP antagonist is a non-biologic CGRP antagonist.
3 . The method of claim 2 , wherein the biologic is an antibody.
4 . The method of claim 3 , wherein the antibody is selected from galcanezumab-gnlm, fremanezumab-vfrm, eptinezumab and erenumab-aooe, and wherein the breakthrough CGRP antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, rimegepant, and vazegepant.
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . The method of claim 1 , wherein the migraine medication used in the underlying treatment comprises a triptan and an antibody.
25 . The method of claim 24 , wherein the triptan is selected from rizatriptan, sumatriptan, naratriptan, eletriptan, donitriptan, almotriptan, frovatriptan, avitriptan, and zolmitriptan.
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . The method of claim 1 , wherein the patient experiences reduced frequency or reduced severity of migraine after treatment with the CGRP antagonist.
30 . The method of claim 1 , wherein the migraine headache, symptom, or episode is selected from sinusitis, nausea, nasopharangytis, photophobia, appetite changes, cognition and concentration difficulties, cold extremities, diarrhea or other bowel changes, excitement or irritability, fatigue, frequent urination, memory changes, weakness, yawning, stretching, seeing bright spots or flashes of light, vision loss, seeing dark spots, tingling sensations, speech problems, aphasia, tinnitus, gastric stasis, pulsating or throbbing pain on one or both sides of the head, extreme sensitivity to light (photophobia), sounds (phonophobia), or smells, worsening pain during physical activity, and vomiting, abdominal pain or heartburn, loss of appetite, lightheadedness, blurred vision, and fainting.
31 . The method of claim 1 , wherein the migraine headache, symptom, or episode is present after the treatment with at least one triptan drug or at least one antibody.
32 . The method of claim 31 , wherein the migraine headache, symptom, or episode is reduced after treatment with the CGRP antagonist.
33 . The method of claim 1 , wherein the CGRP antagonist is administered at a dose of about 1-1000 mg per day.
34 . (canceled)
35 . The method of claim 1 , wherein the CGRP antagonist is administered orally or intranasally.
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . The method of claim 4 , wherein rimegepant is in the form of a hemisulfate sesquihydrate salt.
40 . The method of claim 1 , wherein the pharmaceutical composition is in the form of a tablet or a capsule.
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . The method of claim 1 , wherein the pharmaceutical composition is in the form of an oral solid molded fast-dispersing dosage form.
45 . The method of claim 44 , wherein the pharmaceutical composition comprises from about 70-80 weight % rimegepant hemisulfate sesquihydrate, about 10-20 weight % fish gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of a flavorant.
46 . The pharmaceutical composition of claim 45 , wherein the filler is mannitol.
47 . The method of claim 1 , wherein the pharmaceutical composition is a spayed-dried composition.
48 . The method of claim 47 , wherein the sprayed-dried composition comprises hypermellose succinate acetate and a therapeutically effective amount of a breakthrough CGRP antagonist, or a pharmaceutically acceptable salt thereof.
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . The method of claim 2 , wherein the biologic is a neurotoxic protein and an antibody.
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)